Boehringer Ingelheim Pharmaceuticals, Inc,
Ridgefield, CT, USA
Drulak M is currently working Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA. His/her research interest is based on Verxve 144-Week Results: Nevirapine Extended Release (NVP XR) Qd Versus NVP Immediate Release (IR) Bid with FTC/TDF in Treatment-Naive HIV-1 Patients. He/she has published many articles in reputed journals
HIV/ADS
Journal of AIDS & Clinical Research received 5061 citations as per Google Scholar report